Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance

Amneal Pharmaceuticals, Inc.

2025-Q3 EPS reported $0.11 revenue$2,204,441,000

Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.
Adjusted EBITDA $160M (+1% YoY); adjusted diluted EPS $0.17 (+6% YoY from $0.16).
Specialty +8% driven by CREXONT and UNITHROID; Affordable Medicines +8%; AvKARE +24%.
Incurred $22.5M milestone for XOLAIR biosimilar BLA submission; updated FY2025 guidance.
Launched BREKIYA autoinjector for migraine in October 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.